Purinergic regulation of ENaC in the distal nephron
远端肾单位 ENaC 的嘌呤能调节
基本信息
- 批准号:9899746
- 负责人:
- 金额:$ 34.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AgonistAldosteroneAutomobile DrivingBiological AssayBlood PressureCellsConsumptionDOCADietDiseaseDistalDiureticsElectrophysiology (science)EnvironmentExcretory functionFeedbackFunctional disorderFundingGenesHumanIntakeKidneyKidney DiseasesKnockout MiceLaboratoriesMeasurementMediator of activation proteinMembraneMetabolicModelingMolecular GeneticsMusNatriuresisNephronsP2Y2 receptorParacrine CommunicationPharmacologyPhenocopyPhenotypePhysiologicalReceptor SignalingRefractoryRegulationReninRenin-Angiotensin-Aldosterone SystemResearchSignal PathwaySignal TransductionSodiumSodium ChlorideSystemTamoxifenTelemetryTestingTransgenic MiceUrinalysisUrineWater-Electrolyte Balanceapical membraneblood pressure regulationdesigner receptors exclusively activated by designer drugsepithelial Na+ channelexperimental studygain of functionhormonal signalsloss of functionluminal membranemouse modelnew therapeutic targetnoveloverexpressionparacrinepatch clamppressurereceptorresponsesalt sensitivetranslation to humansurinary
项目摘要
Summary
Discretionary control of renal Na+ transport matches renal Na+ excretion with dietary Na+ intake. Because Na+
excretion can influence blood pressure, disordered renal Na+ transport in many instances causes abnormal
blood pressure. Moreover, as we know from the actions of most diuretics and many tubulopathies interdiction
of normal renal Na+ transport changes blood pressure. Renal sodium excretion is fine-tuned in response to
hormonal signaling in the aldosterone-sensitive distal nephron (ASDN). Within the ASDN, the activity of the
epithelial Na+ channel, ENaC, is the principal mediator of Na+ reabsorption. Consequently, modulation of ENaC
activity is an important regulator of Na+ excretion and blood pressure. ENaC functions as one final effector of
the renin-angiotensin-aldosterone system (RAAS) during the control of blood pressure. Gain and loss of ENaC
function, like RAAS, increases and decreases blood pressure by decreasing and increasing renal Na+
excretion, respectively. Emerging evidence supports that there are other physiologically important signaling
pathways that function in parallel with the RAAS to fine-tune ENaC activity in the ASDN. Previous R01 funded
research from my laboratory demonstrated that a purinergic system intrinsic to the distal nephron regulates
ENaC activity through inhibitory paracrine signaling via apical membrane metabotropic P2Y2 receptors in
principal cells. Our findings have shown that this purinergic system is quantitatively important to the regulation
of ENaC and perhaps consequently, sodium excretion and blood pressure. The latter, though, is only surmised
having been tested indirectly and in a cursory manner. Similar to a gain of ENaC function, dysfunction of
normal paracrine purinergic inhibition of ENaC is predicted to cause salt-sensitivity and increases in blood
pressure as a result of inappropriate Na+ excretion. In contrast, activation of this system is predicted to
promote Na+ excretion. The studies proposed in this resubmission test the premise that inhibitory purinergic
regulation of ENaC contributes to the fine-tuning of renal Na+ excretion and consequently, regulation of blood
pressure. These studies will provide mechanistic understanding and offer a high degree of translation to the
human condition by testing the following three aims: 1) Determine if targeted disruption in the ASDN of
purinergic signaling increases ENaC activity, decreases Na+ excretion and causes salt-sensitivity; 2)
Determine if targeted activation of P2Y2 receptor signaling in the ASDN increases Na+ excretion and can
mitigate to some degree forced salt-sensitivity; and 3) Determine if inhibitory purinergic signaling is important
for ENaC regulation in the human kidney. It is expected that completion of these studies will elaborate a
physiologically important mechanism that contributes to the normal regulation of Na+ excretion; and that when
dysfunctional may cause certain forms of salt-sensitivity; and possibly serve as a novel therapeutic target for
the treatment of elevated blood pressure.
摘要
对肾脏Na+转运的随意控制使肾脏的Na+排泄与饮食中的Na+摄入相匹配。因为Na+
排泄会影响血压,肾脏钠离子转运障碍在许多情况下会导致异常
血压。此外,正如我们从大多数利尿剂和许多肾小管疾病的阻断作用中了解到的那样
正常的肾脏钠离子转运会改变血压。肾钠排泄微调以应对
醛固酮敏感的远端肾单位(ASDN)中的激素信号。在ASDN内,
上皮性钠离子通道(ENaC)是钠离子重吸收的主要介体。因此,ENaC的调制
活性是调节Na+排泄和血压的重要因素。ENAC作为最终效应器发挥作用
肾素-血管紧张素-醛固酮系统(RAAS)在血压控制中的作用。ENaC的得失
像RAAS一样,功能通过减少和增加肾脏Na+来增加和降低血压
排泄物。新出现的证据支持,还有其他重要的生理信号
与RAAS并行发挥作用的通路,以微调ASDN中的ENaC活动。以前的R01资助
我的实验室的研究表明,远端肾单位固有的嘌呤能系统调节
ENAC活性通过顶膜代谢型P2Y2受体抑制旁分泌信号
主细胞。我们的发现表明,这个嘌呤能系统在数量上对调节很重要。
ENaC,也许因此,钠的排泄和血压。然而,后者只是猜测。
以间接和草率的方式进行了测试。类似于ENaC功能的增加,功能障碍
对ENaC的正常旁分泌嘌呤能抑制被预测会导致盐敏感性和血液中的增加
由于不适当的钠离子排泄造成的压力。相比之下,这一系统的激活预计将
促进Na+排泄。这项重新提交试验中提出的研究的前提是抑制性嘌呤能
ENaC的调节有助于微调肾脏的Na+排泄,从而调节血液
压力。这些研究将提供机械性的理解,并提供高度的翻译
通过测试以下三个目标来确定人类状况:1)确定ASDN中是否有针对性的干扰
嘌呤能信号增强ENaC活性,减少Na+排泄,引起盐敏感性;2)
确定靶向激活ASDN中的P2Y2受体信号是否增加Na+排泄和
在一定程度上减轻强制盐敏感性;以及3)确定抑制性嘌呤能信号是否重要
用于人类肾脏的ENaC调节。预计这些研究的完成将制定一项
有助于正常调节Na+排泄的重要生理机制;当
功能障碍可能导致某些形式的盐敏感;并可能成为治疗的新靶点
血压升高的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James D Stockand其他文献
James D Stockand的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James D Stockand', 18)}}的其他基金
Purinergic regulation of ENaC in the distal nephron
远端肾单位 ENaC 的嘌呤能调节
- 批准号:
10132733 - 财政年份:2018
- 资助金额:
$ 34.31万 - 项目类别:
Regulation of renal Na handling in the collecting duct by local purinergic tone
局部嘌呤能调节肾集合管中钠的处理
- 批准号:
7932682 - 财政年份:2010
- 资助金额:
$ 34.31万 - 项目类别:
Regulation of renal Na handling in the collecting duct by local purinergic tone
局部嘌呤能调节肾集合管中钠的处理
- 批准号:
8460882 - 财政年份:2010
- 资助金额:
$ 34.31万 - 项目类别:
Regulation of renal Na handling in the collecting duct by local purinergic tone
局部嘌呤能调节肾集合管中钠的处理
- 批准号:
8077236 - 财政年份:2010
- 资助金额:
$ 34.31万 - 项目类别:
Regulation of renal Na handling in the collecting duct by local purinergic tone
局部嘌呤能调节肾集合管中钠的处理
- 批准号:
8277403 - 财政年份:2010
- 资助金额:
$ 34.31万 - 项目类别:
Epithelial Na channel (ENaC) polymorphisms in hyptertention
高血压中的上皮钠通道 (ENaC) 多态性
- 批准号:
7010908 - 财政年份:2006
- 资助金额:
$ 34.31万 - 项目类别:
Epithelial Na channel (ENaC) polymorphisms in hyptertention
高血压中的上皮钠通道 (ENaC) 多态性
- 批准号:
7229813 - 财政年份:2006
- 资助金额:
$ 34.31万 - 项目类别:
相似海外基金
In vivo and ex vivo lessons from somatic adrenal mutations in cell adhesion molecule 1 for physiological and pathological production of aldosterone
细胞粘附分子 1 体细胞肾上腺突变对醛固酮生理和病理产生的体内和离体教训
- 批准号:
MR/X018970/1 - 财政年份:2023
- 资助金额:
$ 34.31万 - 项目类别:
Fellowship
Creating therapeutic strategies targeting both aldosterone and AGEs-RAGE axis for stopping kidney diseases progression
制定针对醛固酮和 AGEs-RAGE 轴的治疗策略,以阻止肾脏疾病的进展
- 批准号:
23K15240 - 财政年份:2023
- 资助金额:
$ 34.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Processivity and Catalytic Mechanism of Aldosterone Synthase
醛固酮合酶的持续合成能力和催化机制
- 批准号:
10600520 - 财政年份:2023
- 资助金额:
$ 34.31万 - 项目类别:
Aldosterone/mineralocorticoid receptor responses to biologic sex and salt intake: Role of Lysine Specific Demethylase 1 (LSD1)
醛固酮/盐皮质激素受体对生物性别和盐摄入量的反应:赖氨酸特异性脱甲基酶 1 (LSD1) 的作用
- 批准号:
10930190 - 财政年份:2023
- 资助金额:
$ 34.31万 - 项目类别:
Development of a CYP11B2 probe for imaging aldosterone-producing adenomas with high sensitivity.
开发用于高灵敏度对产生醛固酮的腺瘤进行成像的 CYP11B2 探针。
- 批准号:
23H02850 - 财政年份:2023
- 资助金额:
$ 34.31万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
醛固酮阻断用于终末期肾病健康改善评估:延伸
- 批准号:
461992 - 财政年份:2022
- 资助金额:
$ 34.31万 - 项目类别:
Operating Grants
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
- 批准号:
10545747 - 财政年份:2022
- 资助金额:
$ 34.31万 - 项目类别:
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure
利钠肽-肾素-血管紧张素-醛固酮系统节律轴与夜间血压
- 批准号:
10342142 - 财政年份:2022
- 资助金额:
$ 34.31万 - 项目类别:
Role of Renin-Angiotensin-Aldosterone System during sarcoidosis granuloma formation
肾素-血管紧张素-醛固酮系统在结节病肉芽肿形成过程中的作用
- 批准号:
10591934 - 财政年份:2022
- 资助金额:
$ 34.31万 - 项目类别:
Association between excessive salt intake and brain renin-angiotensin-aldosterone system in obesity.
肥胖中过量盐摄入与脑肾素-血管紧张素-醛固酮系统之间的关联。
- 批准号:
22K08167 - 财政年份:2022
- 资助金额:
$ 34.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




